Adalimumab for Ocular Inflammation

作者：Durrani Khayyam; Kempen John H; Ying Gui shuang; Kacmaz R Oktay; Artornsombudh Picha****; Rosenbaum James T; Suhler Eric B; Thorne Jennifer E; Jabs Douglas A; Levy Clarke Grace A; Nussenblatt Robert B; Foster C Stephen^*

来源：Ocular Immunology and Inflammation, 2017, 25(3): 405-412.

DOI：10.3109/09273948.2015.1134581

• Adalimumab
• Humira
• ocular inflammatory disease
• scleritis
• TNF- antibody
• uveitis

Purpose: To evaluate adalimumab as an immunomodulatory treatment for non-infectious ocular inflammatory diseases.Methods: Characteristics of patients treated with adalimumab were abstracted in a standardized chart review. Main outcomes measured were control of inflammation, corticosteroid-sparing effect, and visual acuity.Results: In total, 32 patients with ocular inflammation were treated with adalimumab. The most common ophthalmic diagnoses were anterior uveitis, occurring in 15 patients (47%), and scleritis, occurring in 9 patients (28%). At 6 months of therapy, among 15 eyes with active inflammation, 7 (47%) became completely inactive, and oral prednisone was reduced to 10 mg/day in 2 of 4 patients (50%). On average, visual acuity decreased by 0.13 lines during the first 6 months of treatment. Adalimumab was discontinued because of lack of effectiveness in four patients within 6 months.Conclusions: Adalimumab was moderately effective in controlling inflammation in a group of highly pre-treated cases of ocular inflammatory disease.

• 出版日期2017-6